Squadron Capital Management LLC
Filing Date
Global Rank
#3,603
/ 8,700
▲ 1736
Top Industry
Biotechnology
93.2%
Period ended 2 months ago
Filed Aug 14, 2026 · 30d
3 quarters · since Dec 2025
Portfolio Concentration
38 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
15.8%
−8.1 pts
Top 5
49.4%
−3.0 pts
Top 10
67.8%
−2.1 pts
HHI
681
Diversified−248
Portfolio Trend
3 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $322,245,417 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
10 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | +5,350,000 | 7,600,000 | $35,492,000 | |
| IVA | Inventiva S.A. | +1,900,000 | 2,435,000 | $9,204,300 | |
| LPCN | Lipocine Inc. | +360,000 | 810,000 | $2,073,600 | |
| RLAY | Relay Therapeutics, Inc. | +147,500 | 970,000 | $18,148,700 | |
| KOD | Kodiak Sciences Inc. | +120,000 | 500,000 | $19,480,000 | |
| ZNTL | Zentalis Pharmaceuticals, Inc. | +95,000 | 4,126,000 | $20,011,100 | |
| COGT | Cogent Biosciences, Inc. | +77,508 | 865,000 | $33,475,500 | |
| MAZE | Maze Therapeutics, Inc. | +77,500 | 335,000 | $9,996,400 | |
| AVBP | ArriVent BioPharma, Inc. | +73,000 | 183,000 | $6,357,420 | |
| SLGL | Sol-Gel Technologies Ltd. | +21,000 | 52,000 | $3,855,280 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
7 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| SCYX | Scynexis Inc | −6,851,811 | 756,884 | $3,080,517 | |
| RLMD | Relmada Therapeutics, Inc. | −1,124,571 | 7,350,000 | $50,862,000 | |
| KTTA | Pasithea Therapeutics Corp. | −1,100,000 | 1,000,000 | $515,000 | |
| ANL | Adlai Nortye Group Ltd. | −500,355 | 764,876 | $8,796,074 | |
| IKT | Inhibikase Therapeutics, Inc. | −500,000 | 3,000,000 | $6,090,000 | |
| NXTC | NextCure, Inc. | −200,536 | 64,464 | $103,142 | |
| EWTX | Edgewise Therapeutics, Inc. | −60,000 | 290,000 | $11,782,700 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
19 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| BIOA | BioAge Labs, Inc. | 405,000 | $9,926,550 | |
| CMPS | COMPASS Pathways plc | 605,000 | $8,560,750 | |
| ELVN | Enliven Therapeutics, Inc. | 160,000 | $8,120,000 | |
| RZLT | Rezolute, Inc. | 1,303,410 | $6,777,732 | |
| ADAG | Adagene Inc. | 1,250,000 | $5,250,000 | |
| — | 225,000 | $4,781,250 | ||
| IFRX | InflaRx N.V. | 2,000,000 | $4,480,000 | |
| ASMB | Assembly Biosciences, Inc. | 160,000 | $4,396,800 | |
| CTNM | Contineum Therapeutics, Inc. | 260,000 | $4,261,400 | |
| DFTX | Definium Therapeutics, Inc. | 85,000 | $3,998,400 | |
| PRQR | ProQR Therapeutics N.V. | 1,511,496 | $2,811,382 | |
| IRON | Disc Medicine, Inc. | 30,000 | $2,194,200 | |
| RARE | Ultragenyx Pharmaceutical Inc. | 55,000 | $1,836,450 | |
| CUE | Cue Biopharma, Inc. | 50,000 | $1,578,000 | |
| CALC | CalciMedica, Inc. | 1,244,864 | $1,282,209 | |
| QNCX | Quince Therapeutics, Inc. | 40,375 | $734,421 | |
| NVCT | Nuvectis Pharma, Inc. | 38,700 | $711,693 | |
| INM | InMed Pharmaceuticals Inc. | 325,000 | $503,750 | |
| NMRA | Neumora Therapeutics, Inc. | 100,000 | $170,000 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
14 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ABVX | Abivax S.A. | 130,000 | $14,475,500 | |
| NKTR | Nektar Therapeutics | 125,000 | $8,993,750 | |
| IDYA | IDEAYA Biosciences, Inc. | 224,300 | $7,473,676 | |
| EPRX | Eupraxia Pharmaceuticals Inc. | 680,000 | $4,923,200 | |
| GHRS | GH Research PLC | 325,000 | $4,569,500 | |
| KPTI | Karyopharm Therapeutics Inc. | 750,000 | $4,177,500 | |
| ALXO | Alx Oncology Holdings Inc | 1,460,000 | $2,927,300 | |
| CNTX | Context Therapeutics Inc. | 1,100,000 | $2,882,000 | |
| TRAW | Traws Pharma, Inc. | 511,714 | $936,436 | |
| TXMD | TherapeuticsMD, Inc. | 420,421 | $849,250 | |
| SPRB | Spruce Biosciences, Inc. | 12,200 | $797,270 | |
| HOWL | Werewolf Therapeutics, Inc. | 563,535 | $469,424 | |
| NEUP | Neuphoria Therapeutics Inc. | 76,728 | $312,282 | |
| — | 1,300,100 | $0 | ||
| No positions match the current search. | ||||
38 tracked positions ·
$322,245,417 total
· filing declares
43 positions · $322,245,820
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Reduced | 7,350,000 | $50,862,000 | 15.78% | |
| CCCC |
C4 Therapeutics, Inc.
CALL
+ SHARES
Healthcare
|
Added | 7,600,000 | $35,492,000 | 11.01% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Added | 865,000 | $33,475,500 | 10.39% | |
| ZNTL |
Zentalis Pharmaceuticals, Inc.
CALL
+ SHARES
Healthcare
|
Added | 4,126,000 | $20,011,100 | 6.21% | |
| KOD |
Kodiak Sciences Inc.
Healthcare
|
Added | 500,000 | $19,480,000 | 6.05% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Added | 970,000 | $18,148,700 | 5.63% | |
| EWTX |
Edgewise Therapeutics, Inc.
Healthcare
|
Reduced | 290,000 | $11,782,700 | 3.66% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Added | 335,000 | $9,996,400 | 3.10% | |
| BIOA |
BioAge Labs, Inc.
CALL
+ SHARES
Healthcare
|
NEW | 405,000 | $9,926,550 | 3.08% | |
| IVA |
Inventiva S.A.
Healthcare
|
Added | 2,435,000 | $9,204,300 | 2.86% | |
| ANL |
Adlai Nortye Group Ltd.
Healthcare
|
Reduced | 764,876 | $8,796,074 | 2.73% | |
| CMPS |
COMPASS Pathways plc
CALL
+ SHARES
Healthcare
|
NEW | 605,000 | $8,560,750 | 2.66% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
NEW | 160,000 | $8,120,000 | 2.52% | |
| RZLT |
Rezolute, Inc.
CALL
+ SHARES
Healthcare
|
NEW | 1,303,410 | $6,777,732 | 2.10% | |
| AVBP |
ArriVent BioPharma, Inc.
CALL
Healthcare
|
Added | 183,000 | $6,357,420 | 1.97% | |
| PALI |
Palisade Bio, Inc.
Healthcare
|
Held | 3,000,000 | $6,270,000 | 1.95% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Reduced | 3,000,000 | $6,090,000 | 1.89% | |
| ADAG |
Adagene Inc.
Healthcare
|
NEW | 1,250,000 | $5,250,000 | 1.63% | |
|
|
NEW | 225,000 | $4,781,250 | 1.48% | ||
| IFRX |
InflaRx N.V.
Healthcare
|
NEW | 2,000,000 | $4,480,000 | 1.39% | |
| ASMB |
Assembly Biosciences, Inc.
Healthcare
|
NEW | 160,000 | $4,396,800 | 1.36% | |
| PMN |
ProMIS Neurosciences Inc.
Healthcare
|
Held | 324,977 | $4,276,697 | 1.33% | |
| CTNM |
Contineum Therapeutics, Inc.
Healthcare
|
NEW | 260,000 | $4,261,400 | 1.32% | |
| DFTX |
Definium Therapeutics, Inc.
Healthcare
|
NEW | 85,000 | $3,998,400 | 1.24% | |
| SLGL |
Sol-Gel Technologies Ltd.
Healthcare
|
Added | 52,000 | $3,855,280 | 1.20% | |
| SCYX |
Scynexis Inc
Healthcare
|
Reduced | 756,884 | $3,080,517 | 0.96% | |
| PRQR |
ProQR Therapeutics N.V.
Healthcare
|
NEW | 1,511,496 | $2,811,382 | 0.87% | |
| IRON |
Disc Medicine, Inc.
CALL
Healthcare
|
NEW | 30,000 | $2,194,200 | 0.68% | |
| LPCN |
Lipocine Inc.
Healthcare
|
Added | 810,000 | $2,073,600 | 0.64% | |
| RARE |
Ultragenyx Pharmaceutical Inc.
CALL
Healthcare
|
NEW | 55,000 | $1,836,450 | 0.57% | |
| CUE |
Cue Biopharma, Inc.
Healthcare
|
NEW | 50,000 | $1,578,000 | 0.49% | |
| CALC |
CalciMedica, Inc.
Healthcare
|
NEW | 1,244,864 | $1,282,209 | 0.40% | |
| QNCX |
Quince Therapeutics, Inc.
Healthcare
|
NEW | 40,375 | $734,421 | 0.23% | |
| NVCT |
Nuvectis Pharma, Inc.
CALL
Healthcare
|
NEW | 38,700 | $711,693 | 0.22% | |
| KTTA |
Pasithea Therapeutics Corp.
Healthcare
|
Reduced | 1,000,000 | $515,000 | 0.16% | |
| INM |
InMed Pharmaceuticals Inc.
Healthcare
|
NEW | 325,000 | $503,750 | 0.16% | |
| NMRA |
Neumora Therapeutics, Inc.
Healthcare
|
NEW | 100,000 | $170,000 | 0.05% | |
| NXTC |
NextCure, Inc.
Healthcare
|
Reduced | 64,464 | $103,142 | 0.03% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.